DASATINIB VIATRIS dasatinib 50 mg film coated tablet blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

dasatinib, Quantity: 50 mg

Verfügbar ab:

Helix Pharmaceuticals Pty Ltd

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: magnesium stearate; ethylcellulose; triethyl citrate; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; hyprolose; titanium dioxide; hypromellose

Verabreichungsweg:

Oral

Einheiten im Paket:

60

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

DASATINIB VIATRIS is indicated for the treatment of adults aged 18 years or over with: ? Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase ? Chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib ? Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy

Produktbesonderheiten:

Visual Identification: White to off-white, oval, bevelled-edged, biconvex coated tablet. Engraved "APO" on one side, "DAS50" on the other side; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2018-07-31